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Abstract: IKBKE (IKKε) has emerged as a key modulator of multiple substrates, controlling oncogenic pathways in various malignancies.
mTOR signaling, required for cellular growth, proliferation, and vascular angiogenesis in cancer, is potentially one of the pathways
regulated by IKKε. Upon activation by various stimuli, PI3K/AKT or similar effectors can relieve the inhibitory effect of the TSC1/TSC2
complex through their phosphorylation to favor mTOR/S6K activation in the downstream. Therefore, any activity that interferes with
PI3K/AKT or their downstream targets, such as TSC1/2 or GSK3α/β, may activate the mTOR/S6K pathway for oncogenic transformation
in normal cells. Previous studies have shown that PI3K/AKT can be directly phosphoregulated by IKKε. Here, we propose a new
regulatory function for IKKε in the mTOR/S6K pathway through its direct interaction with TSC1, leading to TSC1 phosphorylation,
which is vital to suppress its inhibitory role in mTOR activation. Experimentally, upon IKKε deficiency in colorectal cancer cells, we
observed that S6K activity was diminished while TSC1 levels were found to be stabilized. We hypothesized that these observations may
result from direct interaction between IKKε and TSC1. Indeed, the interaction of these two proteins involves the phosphoregulation of
TSC1 in various cell lines. Therefore, we propose a mechanism where IKKε, through regulating TSC1 stability in cancer cells, may create
an alternative regulatory loop for the activation of mTOR signaling. These results can potentially be important for the development of
novel therapeutic strategies targeting mTOR signaling.
Key words: TSC1, IKBKE (IKKε), RPS6K1 (P70-S6K1), mTOR, protein synthesis, proliferation, cancer

1. Introduction
mTOR is a serine/threonine kinase and component of
two distinct multiprotein complexes called mTORC1
and 2 (mTOR complex 1 and 2). mTORC1 is composed
of mTOR, Raptor (RPTOR, regulatory-associated protein
of mTOR), mLST8 (mTOR associated protein, LST8
homolog), DEPTOR (DEP domain containing mTOR
interacting protein), and Pras40 (a.k.a. AKT1S1, prolinerich Akt substrate 40kDa). mTORC1 can be inhibited by
rapamycin (Laplante and Sabatini, 2012; AlQurashi et al.,
2013). mTORC2 is composed of mTOR, Rictor (RPTOR
independent companion of mTOR complex 2), mLST8,
MAPKAP1 (a.k.a. Sin1, mitogen-activated protein kinase
associated protein 1), PRR5/Protor-1 (proline rich 5 like),
and DEPTOR. mTOR can receive signals from diverse
upstream factors, such as growth factors, energy sources,
stress, and other metabolites, to control major cellular
machinery in cell growth, autophagy, protein synthesis,
and lipid biosynthesis (Laplante and Sabatini, 2012;
Saxton and Sabatini, 2017). Aberrant mTOR activation is
* Correspondence: goktuna@bilkent.edu.tr
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observed in many diseases such as cancer, cardiovascular
disease, and diabetes (Dowling et al., 2010).
mTORC1 complexes can also be negatively regulated
by upstream signals from hypoxia, low ATP levels, or
genotoxic stress, which in turn activate inhibitory proteins
such as AMPK (5’ AMP-activated protein kinase) or
TSC1/2 (tuberous sclerosis 1 and 2) (AlQurashi et al.,
2013). TSC1/2 heterodimers are especially important
in inhibiting mTORC1 activity upon stress signals
(Inoki et al., 2005). Mechanistically, TSC1/2 inactivate
mTORC1 by converting GTP-bound active Rheb (Ras
homolog enriched in brain), an essential component for
mTORC1 activity, to its GDP-bound inactive form (Inoki
et al., 2003a). Regulation of TSC1/2 activity involves
transmission of various growth signals (RTKs, Wnt, etc.),
which eventually stimulate central signaling hubs, such as
PI3K and Ras proteins, to activate oncogenic PI3K/Akt or
Ras/RAF/MAPK signaling cascades (Saxton and Sabatini,
2017). These signaling cascades, in turn, promote the
activation of downstream effectors such as AKT (serine/

GÖKTUNA / Turk J Biol
threonine kinase 1/v-Akt murine thymoma viral oncogene
homolog), ERK1/2 (extracellular-signal-regulated kinase
1/2), and RSK1 (ribosomal S6 kinase) (Inoki et al., 2002;
Manning et al., 2002; Potter et al., 2002; Roux et al.,
2004; Ma et al., 2005). These kinases can then directly
phosphorylate TSC1/2 to halt their inhibitory effect on
mTORC1 activation (Laplante and Sabatini, 2012).
Not limited to PI3K/Akt and Ras/MAPK regulations,
the mTORC1 pathway can also be controlled via diverse
effectors that directly or indirectly interfere with TSC1/
TSC2 stability. While phosphorylation of TSC1/2 leading
to its ubiquitination and degradation by some of these
effectors can limit TSC1/2 stability, phosphorylation
of some other residues on TSC2 (namely T1271, S1371,
S1373, S1379, S1383, and S1387) by AMPK or GSK3α/β
can render TSC1/2 heterodimers more stable and potent
(Inoki et al., 2003b, 2006; Huang and Manning, 2008).
However, GSK3 and AMPK are also targeted by diverse
pathways that limit their activity in a similar manner. For
example, the Wnt pathway may activate mTORC1 through
GSK3β (glycogen synthase kinase 3β) phosphorylation,
which primes GSK3 to proteasomal degradation (Inoki et
al., 2006). TSC1/2 activity can also be negatively regulated
via GSK3α phosphorylation mediated by AKT (Huang,
2009) or S6K1 kinase (Zhang et al., 2006). Finally, TSC1/2
can be phosphoregulated by IKKβ (IκB kinase β) in
response to TNFα (tumor necrosis factor-α) stimulation
in lung tumors (Lee et al., 2007).
Activation of mTOR (mechanistic targets of rapamycin)
signaling may promote oncogenic processes, such as
survival, proliferation, growth, motility, and angiogenesis,
which are essential for tumor initiation, progression, and
metastasis. Accumulating evidence shows the involvement
of the deregulated mTOR pathway in various malignancies
including breast, skin, lung, colorectal, and liver cancers
(Saxton and Sabatini, 2017). Likewise, the development
of certain hereditary cancers is linked to the mutations
in genes coding for the upstream elements of the mTOR
pathway. Parallel to these findings, certain elements of the
PI3K (phosphatidylinositol 3 kinase) pathway, upstream
of mTOR, are found to be frequently mutated in diverse
malignancies (Saxton and Sabatini, 2017). Some examples
are KRAS (Kirsten rat sarcoma 2 viral oncogene homolog),
RAF (v-Raf murine leukemia viral oncogene homolog),
PTEN (phosphatase and tensin homolog), TSC1/2
(tuberous sclerosis 1/2), LKB1 (serine threonine kinase
11), and NF1 (neurofibromin 1) (Laplante and Sabatini,
2012). Similarly, p53 (TP53, tumor protein p53) loss, a
common theme in many cancers, may promote mTOR
activation, leading to enhanced tumor growth (Feng et al.,
2005).
Highly proliferative tumor cells usually require
augmented levels of protein synthesis and other anabolic

pathways for their increased cellular growth and cell
division rates. Findings from many recent studies support
the idea that deregulated protein synthesis has a central
role in tumor development. For instance, mTORC1
phosphoactivates S6K1 (ribosomal protein S6 kinase
B1), which in turn activates ribosomal protein S6 (Saitoh
et al., 2002; Jastrzebski et al., 2007). The latter, together
with mTORC1, orchestrates activities of two important
downstream factors, namely 4E-BP1 (eukaryotic
translation initiation factor 4E-binding protein 1) and
eIF4E (eukaryotic translation initiation factor 4E1),
which are the major regulators of protein synthesis at
ribosomes (Bianchini et al., 2008). These factors are found
to be deregulated in numerous malignancies (Saxton and
Sabatini, 2017). In particular, eIF4E and its downstream
axis can favor tumor progression and metastasis through
enhanced translation of prooncogenic proteins involved in
mechanisms such as survival, proliferation, angiogenesis,
energy metabolism, and EMT (Laplante and Sabatini,
2012). Although S6K and its downstream targets are very
important for tumor cell growth and proliferation, their
contribution to the oncogenic properties of ERK and/
or AKT signaling seems to be very limited (Hsieh et al.,
2010; She et al., 2010). Hence, not all proteins that control
protein synthesis under the mTOR signaling pathway are
equally crucial in oncogenic transformation.
IKK-related kinases, namely TBK1 (TANK binding
kinase) and IKKε (inhibitor of κB kinase epsilon), have
been associated with the development of numerous
cancers in tissues from ovarian, breast, lung, colorectal,
prostate, skin, nerve, and pancreatic origin (Hsu et al.,
2012; Barbie et al., 2014; Challa et al., 2016; Göktuna
et al., 2016; Zubair et al., 2016; Lu et al., 2017; Péant et
al., 2017). As a result, TBK1 and IKKε have emerged as
potential targets for cancer therapy in many malignancies
(Kim et al., 2013; Niederberger et al., 2013). Accumulating
evidence supports that IKK-related kinases orchestrate
tumor cell survival upon genotoxic stress by the direct
regulation of the master regulators of cell survival like
AKT and NF-κB (Chau et al., 2008; Guo et al., 2011; Xie et
al., 2011). Although detailed mechanisms may be different
from one cancer to another, there is a common theme of
IKK-related kinase involvement in the regulation of the
survival pathways through maintaining constitutive ERK
and AKT activations (Göktuna et al., 2016). Here, we
describe a novel regulatory link between IKKε and TSC1
in a colorectal cancer cell line, in which TSC1 stability
is directly controlled via phosphorylation by IKKε to
maintain tumor cell growth. We believe that this new
regulatory circuitry on TSC1 function may be important
for oncogenic transformation in various malignancies and
the information we obtained here will be instrumental for
developing more powerful therapeutic strategies to tackle
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cancer.
2. Materials and methods
2.1. Cell lines, tissue culturing, and transfections
SW480 cells (ATCC, USA) were maintained in L-15
medium (Sigma, USA) supplemented with 10% FCS
(Sigma, USA), 1% L-glutamine, and 1% penicillinstreptomycin (Lonza, Switzerland). HEK293 cells (ATCC,
USA) were maintained in DMEM (Lonza, Switzerland)
supplemented with 10% FCS, 1% L-glutamine, and 1%
penicillin-streptomycin. All transfections were carried out
in Opti-MEM (GIBCO/Thermo, Germany) medium with
Transfectin (Bio-Rad, USA) or TransIT-X2 (MirusBio,
USA) for plasmid DNA or with Hiperfect (QIAGEN, USA)
for siRNA constructs as described by the manufacturers.
siRNA (Eurogentec, Belgium) and shRNA constructs
(Sigma, USA) were used for human IKBKE (IKKε) or
human IKBKB (IKKβ) gene silencing. All depletions and
overexpressions were controlled via changes in protein
levels by the use of specific antibodies in western blotting
(WB).
2.2. Plasmids
pCDNA3.1-myc-TSC1 and pRK7-FLAG-TSC1 plasmids
were bought from Addgene (USA). pGST-6P-1-TSC1
(400-500/S487A) and pGST-6P-1-TSC (501-600/S511A)
plasmids were given by Dr Hung (MD Anderson Cancer
Center, TX, USA) and TSC1 phosphorylation sites in
these constructs were restored by the use of site-directed
mutagenesis (Stratagene, USA) as described by the
manufacturer. pCMV or pCDNA3 based myc-IKKεWT
and myc-IKKεKD (K38A) expression plasmids were
generated by Dr Kateryna Shostak in our group from the
source plasmid, pLK5-IKKε, provided by Dr Ivan Dikic
(Frankfurt University, Germany).
2.3. Western blotting, immunoprecipitations, and kinase
assays
All procedures were performed as described previously
(Göktuna et al., 2014, 2016). Briefly, 8%–12% SDS-PAGE
gels were used for the separation of proteins from cell
lysates. Then these gels were blotted onto PVDF membranes
(Millipore, USA) and target proteins (coupled with
specific primary and HRP-linked secondary antibodies)
were visualized by the use of chemiluminescence reagent
(Pierce/Thermo, Germany) and X-ray film (Fujifilm,
Japan). Immunoprecipitation reactions were carried out
with Protein A or Protein G agarose beads (SCBT, USA)
and specific antibodies. Cell lysates were incubated with
agarose beads and antibody mixture by gentle rotation at
4 °C for 4 h. Next, the beads were washed 3 or 4 times
with cell lysis buffer. These beads were used for WB or
in vitro kinase assay accordingly. For the in vitro kinase
assay, endogenous or overexpressed kinases were pulled
out from cell lysate by IP and incubated with substrate,

270

free ATP, and 32P-γ-ATP (PerkinElmer, USA) for 30 min
at 30 °C. The beads were boiled at 95 °C in SDS-PAGE
loading buffer to extract proteins, which were then blotted
via WB. The blotted PVDF membranes were the visualized
via autoradiography to detect relative kinase activities on
target substrates. Antibodies used were anti-IKKε #I4907
(Sigma), anti-phospho-S6K (T389) #9205 (CST), antiTSC1 #4906 (CST), anti-TBK1 #3013 (CST), anti-S6K
#sc-8418 (SCBT), anti-tubulin #T9026 (Sigma), anti-IKKâ
#05-535 (Upstate/Millipore), anti-Myc #sc-764 (SCBT),
and anti-FLAG-M2 #F3165 (Sigma). WB band intensities
were calculated by densitometric gel analysis tools in
ImageJ Software (NIH, USA).
2.4. Statistics
For statistical analysis of the expression data, Student’s
t-test was used. In this test, P < 0.05 was considered
significant. All statistical analyses were performed with
Prism Software (GraphPad, USA).
3. Results
3.1. Signal-dependent S6K activation is abrogated in the
absence of IKKε
To characterize cellular signaling pathways regulated by
IKBKE in colorectal cancer cell lines, we utilized loss-offunction models in which the IKBKE gene was silenced in
SW480 cells by the use of specific siRNAs targeting IKBKE
transcripts. Forty-eight hours after siRNA transfection,
cells were subjected to various stimuli such as serum
withdrawal (0.1% FCS instead of 10%), LPS stimulation (10
ng/mL), or TNF stimulation (100 ng/mL) for an additional
24 h to investigate different signaling machinery involved
(Figure 1). Cells were then harvested and the protein
samples were isolated to quantify relative changes in the
expression or phosphorylation of target proteins. Results
showed successful silencing of IKBKE as evidenced by
its protein levels (Figure 1A, samples 2, 4, 6, and 8). Of
note, this silencing is specific, since the protein level of the
other IKK-related kinase TBK1 (Figure 1A, lane 2) was
not affected. More importantly, in the absence of IKBKE
and upon any stress condition, S6K activation was totally
abrogated as determined by the phosphospecific S6K
antibody (Figure 1A, lane 3) compared to control samples
of GFP targeting siRNA. Therefore, S6K phosphoactivation
seems to be correlated with the presence of IKKε and the
growth-supporting functions of S6K may not be sustained
upon IKKε loss in SW480 cells. This may explain the
reduced tumor growth in IKKε-deficient mice tumors that
we described before (Göktuna et al., 2016).
3.2. TSC1 is stabilized upon IKBKE loss in SW480 cells
To better understand the nature of regulation on S6K
upon IKKε loss in SW480 cells, further analyses of
upstream molecules controlling S6K were carried out.
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Figure 1. S6K cannot be activated in the absence of IKKε. SW480 cells were first silenced with IKKε siRNA for 48 h and later treated with
either no serum, 10 ng/mL LPS, or 100 ng/mL TNFα for an additional 24 h for the activation of the mTOR/S6K pathway. Upon IKKε
silencing, p70-S6K phosphorylations were seriously diminished in all stress conditions relative to the control. A) WB results for IKKε,
TBK1, phospho-S6K, and S6K proteins by the use of specific antibodies. B) Quantification of phospho-S6K/S6K band intensities in WB
(for p-S6K quantifications only heavy isoform has been used since total antibody only recognizes this isoform).

For this purpose, IKBKE was silenced in SW480 cells
but we only used LPS (10 ng/mL) stimulation (0–5 h) to
activate mTOR and its downstream targets. As a result,
we observed a strong reduction in S6K phosphoactivation
(Figure 2A, lane 1, and Figure 2B) in the absence of IKKεâ
while mTOR phosphorylation was not affected (Figure 2A,
lane 3). Therefore, the potential IKKε regulation on S6K
is not through mTORC1 but an alternative pathway. One
such candidate could be mTOR inhibitor TSC1. To verify,
we checked TSC1 protein levels upon IKKε silencing and
we found that TSC1 was strongly stabilized in the absence
of IKKε in SW480 cells (Figure 2A, lane 4, and Figure 2C).
These observations collectively suggested the existence of
a novel regulatory function for IKKε to control TSC1 or
S6K activities.
As shown in previous studies, IKKβ (a related
IκB kinase) controls TSC1/2 stability through direct
phosphorylation (Lu et al., 2007). We therefore wanted
to compare relative effects of IKBKE or IKBKB silencing
on TSC1 stability. For this purpose, we transfected SW480
cells with siRNAs against IKBKE or IKBKB and GFP as the
control, followed by LPS stimulations after 48 h. LPS (10
ng/mL) was used up to 1 h when peak activation of IKKε
was observed. The depletion of IKKε or IKKα (Figure 3A,
lanes 2 and 3) protein levels was confirmed by WB (Figure
3A; quantified in Figure 3B). Upon LPS stimulation in
control samples, TSC1 levels were observed to be first
increased upon 30 min of treatment but then reduced
back to normal levels after 1 h (Figure 3A, lane 1, and
its quantification in Figure 3B). In the absence of IKKβ
or IKKε, however, TSC1 protein levels were observed

to be higher than in control samples at 30 min or 1 h of
LPS treatment. In a sharp contrast to the TSC1 level of
control samples, an increased TSC1 level was sustained
even after 1 h of LPS treatment upon IKKε or IKKβ
deficiency. Interestingly, TSC1 stabilization was even more
pronounced in the absence of IKKε than that of IKKβ in
SW480 cells (Figure 3A, lane 1, and its quantification in
Figure 3B).
To understand if the regulation on TSC1 stability by
IKKε is at a transcriptional or posttranslational level, we
first checked TSC1 and TSC2 mRNA expression. From
the analysis of the RNA-Seq data from our previous
work (Göktuna et al., 2016), we found that the mRNA
expressions of TSC1 or TSC2 (Figures 3C and 3D) were
not different in intestinal epithelial samples of wt or
Ikbkeko mice in a Wnt-dependent tumor model (β-catc.a. –
or constrictively active â-catenin– is short for Villin-CreERT2/Ctnnb1+/lox(ex3) mice (Göktuna et al., 2014)). Then
we also checked the TSC1 mRNA levels via qRT-PCR in
control versus IKBKE-silenced SW480 cells (Figure 3E).
Concomitantly, we did not observe any change in TSC1
expression upon IKKε depletion. Therefore, we concluded
that IKKε regulates TSC1 posttranslationally.
3.3. TSC1 directly interacts with IKBKE and is
phosphorylated by this kinase
To elucidate the nature of interaction between TSC1
and IKKε, we ectopically expressed FLAG- or MYCtagged proteins in HEK293 cells (Figure 4A) Expression
levels of each protein were measured in WB by the use
of anti-FLAG or anti-Myc antibodies (Figure 4A, lanes
1 and 2). Noticeably, ectopically expressed Myc-TSC1
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Figure 2. S6K inactivation and TSC1 stabilization correlate upon IKBKE silencing. SW480 cells were silenced with IKKε siRNA
(please refer to Göktuna et al., 2016 for depletion controls such as IKKε and α-tubulin western blots; data are obtained from a similar
experimental setup) for 48 h and then they were treated with 10 ng/mL LPS for 0 to 5 h for the activation of mTOR/S6K and IKKε.
According to WB results, only S6K (A) activation, not mTOR (B), was diminished in the absence of IKKε (as quantified by phosphoS6K/S6K densitometric band intensities) and S6K inactivation was inversely correlating with the stabilization of TSC1 (as quantified in
(C)).

showed a clear upshift only when it was coexpressed
with FLAG-IKKε (Figure 4A, lane 2). This upshift
might be due to phosphorylation of TSC1 by IKKε. To
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examine this hypothesis, we first tested the possibility
of an interaction between these proteins by the use of
coimmunoprecipitation (co-IP) assay after ectopically
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Figure 3. IKKε deficiency affects the posttranslational stabilization of TSC1. siRNAs targeting IKKε or IKKβ (siRNA-GFP used as
mock) were used for silencing respective genes in SW480 cells for 48 h, and then cells were treated with LPS (10 ng/mL) for 0 to 1 h for
the activation of related signaling pathways (m: minutes). As a result of WB by the use of specific antibodies, TSC1 protein levels were
observed to be stabilized especially upon IKKε silencing in SW480 cells (A) (as quantified by densitometric band intensities in ImageJ
(B)). RNA-Seq data from our previous study (Göktuna et al., 2016) was analyzed for relative TSC1 (C) or TSC2 (D) mRNA expressions
in wt (β-catc.a./Ikbke+/+) or Ikbkeko (β-catc.a./Ikbke-/-) intestinal epithelial tumor samples and we found no effect on their transcription. TSC1
mRNA expression was also checked by RT-PCR in IKBKE-silenced SW480 cells (by transfecting control vs. two different IKBKE siRNA
constructs) (E) and still no differences in TSC1 mRNA expressions were noted as a result of IKKε deficiency.

expressing both proteins together in HEK293 cells (Figure
4B). As a result, we found that IKKε and TSC1 proteins
physically interact when ectopically expressed (Figure 4B,

right and left panels).
Since no endogenous interaction between IKKε and
TSC1 could be detected (results not shown), we thought
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Figure 4. TSC1 interacts with IKKε and is phosphorylated by this kinase. A) FLAG-TSC1 and Myc-IKKε constructs were ectopically
expressed in HEK293 cells as indicated. TSC1 shows a phosphospecific shift (lane 2) upon coexpression with IKKε in HEK293 cells.
B) FLAG-TSC1 and Myc-IKKε constructs were ectopically expressed in HEK293 cells as indicated. Then Myc-IKKε constructs were
harvested from the cell lysates with anti-Myc antibody and coprecipitated proteins were analyzed by western blot. FLAG-TSC1 was
observed to bind to IKKε in two separate trials (right and left panels). C) Myc-IKKεwt or Myc-IKKεKD proteins were ectopically expressed
in HEK293 cells and these kinases were harvested from cell lysates with immunoprecipitation by the use of anti-Myc antibody. Then
GST-TSC1 (500-600) substrates were used for in vitro kinase assay. Only Myc-IKKεwt was observed to phosphorylate the TSC1 substrate
from the putative S511 site (lane 1).

that their interaction could be transient, as in the case of
many other similar interactions involving a kinase and
its substrate (Sommese and Sivaramakrishnan, 2016).
Next, we tested if TSC1 is a direct substrate for IKKε by
performing an in vitro kinase assay (Figure 4C). Briefly, we
used a short fragment (amino acids 500–600, containing
the putative S511 phosphorylation site) of recombinant
human-GST-TSC1 as a substrate and ectopically expressed
Myc-IKKεWT or Myc-IKKεKD (kinase dead, K38A) proteins
(harvested from HEK293 via IP) as kinase in the assay. As
a result, only catalytically active IKKε (Myc-IKKεWT) could
phosphorylate the GST-TSC1500-600 substrate (Figure 4C,
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lane 1), suggesting that TSC1 is a direct substrate for IKKε.
4. Discussion
In our previous studies aiming to understand IKKε
involvement in colorectal tumorigenesis, we observed
strong downregulation in phosphorylations of AKT and
ERK1/2 kinases, whose activities were found to be essential
for the survival of tumor cells upon genotoxic stress or
oncogenic transformation (Göktuna et al., 2016). Indeed,
we have confirmed a direct phosphoregulatory control on
AKT by IKKε in CRC cell lines (data not shown). These
observations were consistent with the previous findings
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Figure 5. Proposed mechanism of TSC1 and IKKε interaction in tumor cells. Here we propose a new
regulatory connection for sustaining mTOR/S6K signaling via direct phosphoregulation of TSC1 by IKKε
in transformed colorectal cancer cells (the new link is shown in bold).

in inflammatory cells (Guo et al., 2011; Xie et al., 2011).
We concluded that downregulation of AKT and ERK
phosphoactivation may explain the reduced growth of
mouse colorectal tumors through increased apoptosis in
the absence of IKKε (Göktuna et al., 2016). However, our
observations on IKKε involvement in CRC tumorigenesis
were not limited to these survival kinases. IKKε loss has
pleiotropic effects on colorectal cancer cells varying from
increased apoptosis to loss of proinflammatory cytokine
expression and reduced tumor growth in various tumor
models (Göktuna et al., 2016). Therefore, in this study, we
investigated if IKKε is also involved in other mechanisms
related to oncogenic transformation by the use of IKKε
loss-of-function models in cancer cell lines.
Results of the experiments showed a robust
downregulation of downstream targets in the mTOR
pathway upon IKKε loss. One plausible explanation could
be that IKKε deficiency leads to downregulation of mTORC
activity due to diminished AKT phosphoactivation (Xie
et al., 2011; Huang and Fingar, 2014). Moreover, it is also
possible that IKKε may directly phosphorylate the mTORC
complex, similarly to the IKK-related kinase TBK1 upon
growth factor or innate immunity agonist stimulation
in immune cells (Bodur et al., 2018). However, direct
interference by IKKε on mTORC or its upstream elements
like AKT can be ruled out in this case, since mTOR

phosphorylation is not affected in SW480 cells. Moreover,
the ability of mTOR to induce S6K activity does not solely
depend on mTOR phosphorylation. The mTOR complex
can also be regulated by inhibitory molecules like TSC1,
AMPK, or GSK3α/β. As described earlier, TSC1/2 can
also prevent mTORC-driven S6K activation by converting
Rheb-GTP to its inactive form (Laplante and Sabatini,
2012). Numerous reports suggested that TSC1/2 can be
directly phosphoregulated via different effectors such as
AKT, ERK, RSK, and IKKα (Saxton and Sabatini, 2017),
some of which can also regulate GSK3α/β activities. On the
other hand, IKK-related kinase TBK1 was also shown to
activate mTORC1 through phosphoregulating inhibitory
AMPK in adipocytes (Zhao et al., 2018). Consequently,
we hypothesized that IKKε may be directly or indirectly
regulating TSC1/2 activity as suggested by stabilized
TSC1 protein levels upon IKKε deficiency. The indirect
regulation hypothesis was finally ruled out since we did
not observe any difference in GSK3α/β phosphorylation
upon IKKε deficiency (data not shown). Hence, we
concentrated on IKKε-mediated regulations over S6K and
its upstream inhibitor TSC1 in colorectal cancer cell lines.
As a result, we identified a unique regulatory connection
within mTOR/S6K signaling in which TSC1 stability can
be controlled via its phosphorylation by IKKε. This new
regulatory mechanism is most probably independent of
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AKT or mTORC regulation by IKKε (Xie et al., 2011; Bodur
et al., 2018) since mTOR or GSK3α/β phosphorylations
were not affected. The proposed mechanism for this new
regulatory circuit is summarized in Figure 5. We believe that
this is the first report that demonstrates a direct interaction
between IKKε and TSC1. The biological function of the
observed results in tumor cell growth or survival are yet to
be elucidated with more comprehensive studies.
Targeting mTORC and its downstream elements
in cancer has long been thought to be a prominent
strategy since mTORC acts as an environmental sensor
of various stimuli (e.g., from cytokine, growth, or death
receptors) to activate downstream molecules for oncogenic
transformation (Zoncu et al., 2011). Currently there are
numerous preclinical and clinical studies determining the
therapeutic potential of usage of rapamycin and its analogs
(rapalogs) for the inhibition of mTOR signaling or related
pathways. However, the success and efficiency of such
approaches are seriously limited due to the existence of
negative feedback loops within mTOR signaling (Sun et al.,
2015; Saxton and Laplante, 2017). For example, mTORC1
(directly) or S6K1 (indirectly) can mediate insulin receptor
substrate-1 (IRS-1) phosphorylation and its subsequent
degradation leads to desensitization of RTKs to growth
factors as a feedback inhibition (cited in Laplante and
Sabatini, 2012). Similarly, regulatory pathways can result in
reduction of RTK expression like the one through plateletderived growth factor receptors (PDGFRs), whose detailed
mechanism is yet to be identified (Saxton and Sabatini,
2017). Therefore, we need a better understanding of mTOR
signaling and its downstream regulatory circuits to develop
superior therapeutic strategies in cancer therapy.
IKKε is known to have diverse substrates in many
various signaling pathways, resulting in alternative or
bypass mechanisms for continuation of transmitting the
signals or providing cross-talk between others (Chau et

al., 2008; Shen and Hahn, 2011). IKKε-mediated control of
mTORC1, AKT, or TSC1 suggests the existence of multiple
simultaneous control steps within mTOR signaling. The
results obtained in this report also illustrate tissue and cell
specificity of certain regulatory circuits and help to widen
our understanding of signaling networks, their cross-talk,
and their regulation by effector molecules. Identification of
signaling networks linked with IKK-related kinases may
offer unique opportunities to find alternative therapeutic
approaches for fighting against cancer. In a related
study, it was shown that IKKε activity is essential for the
survival of pancreatic cancer cells upon mTOR inhibition
(Rajurkar et al., 2017). Additionally, another study pointed
out that TBK1 may provide the activation of the AKT/
mTOR pathway in lung tumorigenesis depending on the
context (Cooper et al., 2017). Therefore, the combination
of mTOR and IKK-related kinase inhibition may prove
a strong strategy to tackle cancers where cancer cell
growth is primarily dependent on these pathways. These
combinatorial approaches may circumvent the drawbacks
associated with mTOR inhibition and can provide
better therapeutic alternatives for the development of
personalized cancer therapies.
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